Related Experiment Video
Updated: Apr 3, 2026
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Heterogenous Model of Temozolomide Resistance in Glioblastoma Reveals Phenotypic Shifts in Drug Response and
Victoria A Kriuchkovskaia1,2, Ela K Eames1, Sydney A McKee2,3
1Dept. Chemical and Biomolecular Engineering, University of Illinois at Urbana-Champaign, Urbana, IL, USA.
Abstract:
Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor in adults, with limited survival outcomes due to tumor recurrence, mainly driven by GBM cell invasion and therapy resistance. Although temozolomide (TMZ) remains the standard-of-care chemotherapeutic, its long-term efficacy is often compromised by rapid emergence of acquired resistance, largely mediated by the DNA repair enzyme, methylguanine methyltransferase (MGMT). To investigate the interplay between tumor heterogeneity, drug resistance, and the extracellular matrix (ECM) microenvironment, we adapted a 3D methacrylamide-functionalized gelatin (GelMA) hydrogel model to study the behavior of mixed populations of TMZ-sensitive and TMZ-resistant GBM cells. Using both single-cell distributions and multicellular spheroids, we report the impact of heterogeneous cell populations and TMZ dosing regimens, including physiological, supraphysiological, and metronomic TMZ schedules, on drug response and migration. We show that the combination therapy of TMZ with an MGMT inhibitor, lomeguatrib, can modulate TMZ resistance in vitro. This hydrogel model enables systematic investigation of GBM heterogeneity, "go-or-grow" phenotypic plasticity, and therapeutic resistance in an ECM-rich microenvironment, offering a valuable platform for future translational research.
Insights
Glioblastoma (GBM) drug resistance can be overcome by combining temozolomide (TMZ) with an MGMT inhibitor. This study used a 3D hydrogel model to explore GBM heterogeneity and improve therapeutic strategies.
Area of Science:
- Neuro-oncology
- Biomaterials Science
- Cancer Biology
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with poor outcomes due to recurrence and therapy resistance.
- Temozolomide (TMZ) is the standard chemotherapy, but acquired resistance, often mediated by MGMT, limits its efficacy.
- Understanding GBM heterogeneity and the extracellular matrix (ECM) microenvironment is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the impact of GBM cell heterogeneity and drug resistance within an ECM-rich microenvironment.
- To evaluate the efficacy of different temozolomide (TMZ) dosing regimens and combination therapy with an MGMT inhibitor.
- To establish a 3D hydrogel model for studying GBM behavior and therapeutic resistance.
Main Methods:
- Developed a 3D methacrylamide-functionalized gelatin (GelMA) hydrogel model.
- Studied mixed populations of TMZ-sensitive and TMZ-resistant GBM cells using single-cell distributions and multicellular spheroids.
- Assessed the effects of various TMZ dosing schedules (physiological, supraphysiological, metronomic) and combination therapy with lomeguatrib (an MGMT inhibitor).
Main Results:
- Demonstrated the impact of heterogeneous GBM cell populations and TMZ dosing on drug response and migration within the 3D hydrogel.
- Showed that combining TMZ with the MGMT inhibitor lomeguatrib can modulate TMZ resistance in vitro.
- Validated the utility of the GelMA hydrogel model for simulating GBM's complex microenvironment.
Conclusions:
- The 3D GelMA hydrogel model provides a valuable platform for studying GBM heterogeneity, phenotypic plasticity, and therapeutic resistance.
- Combination therapy with TMZ and an MGMT inhibitor shows promise for overcoming drug resistance in GBM.
- This model facilitates translational research for improved GBM treatment strategies.
